AHA GUIDELINES Bundle (free trial)

Supraventricular Tachycardia

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/600060

Contents of this Issue

Navigation

Page 25 of 33

Treatment Junctional Tachycardia Table 17. Acute Treatment of Junctional Tachycardia COR LOE Recommendations IIa C-LD IV beta blockers are reasonable for acute treatment in patients with symptomatic junctional tachycardia. IIa C-LD IV diltiazem, procainamide, or verapamil is reasonable for acute treatment in patients with junctional tachycardia. Table 18. Ongoing Management of Junctional Tachycardia COR LOE Recommendations IIa C-LD Oral beta blockers are reasonable for ongoing management in patients with junctional tachycardia. IIa C-LD Oral diltiazem or verapamil is reasonable for ongoing management in patients with junctional tachycardia. IIb C-LD Flecainide or propafenone may be reasonable for ongoing management in patients without SHD or ischemic heart disease who have junctional tachycardia. IIb C-LD Catheter ablation may be reasonable in patients with junctional tachycardia when medical therapy is not effective or contraindicated. Figure 12. Ongoing Management of Junctional Tachycardia Junctional tachycardia Beta blockers, diltiazem, or verapamil (Class IIa) Flecainide or propafenone (in the absence of SHD) (Class IIb) Drug therapy options Catheter ablation (Class IIb) If ineffective or contraindicated 24

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Supraventricular Tachycardia